Progression of cyclosporine A-blood levels in experimental cats receiving a high-dose treatment protocol

• DOI: 10.3389/fvets.2024.1444586
• Publication Date: 2024-10-16T05:11:21Z
• Authors: Sarah Rösch; Anna Frommeyer; Jenny Schulte Boc...; Denis Grote-Koska; Korbinian Brand; Reinhard Mischke
• Keywords: Dose; Ciclosporin

Background Cyclosporine A (CsA) is used as a steroid-sparing or alternative immunosuppressing agent in cats with various immune-mediated diseases such hemolytic anemia. Daily treatment dosages of 5–20 mg/kg have been described. Interindividual variations CsA blood levels are known to occur. To determine when steady-state conditions reached and thus the earliest advisable time for monitoring during course treatment, prospective experimental study was conducted six healthy adult Domestic Shorthair cats. Materials methods Cats were treated an oral dosage 7 q 12 h 10 days. On days 1, 2, 3, 5, 7, after start administration (i.e., 9, 13, 19 administrations), EDTA collected measure level (trough values) using high-performance liquid chromatography coupled mass spectrometry (HPLC-MS/MS). Results Statistical analysis revealed significant increase mean up day 5 (2,050 ± 964.2 ng/mL [mean SD], 832–3,203 [minimum–maximum]; repeated-measures ANOVA: p = 0.0021), while values on did not differ significantly from concentrations 10. showed markedly interindividual variability. Conclusion steady state high nine indicating that this point suitable clinical patients. confirmed well-known remarkable variability CsA, need monitoring. The assessed regime resulted higher trough than target range immunosuppressive therapy (200–600 ng/mL).